INTRADERMAL INJECTION DEVICE

An intradermal injection device comprising a unitary body having an open distal end and a proximal end having a skin engaging surface defined thereon, a reservoir defined between the proximal and distal ends for accommodating a drug substance, and a channel defined at the proximal end of the unitary body and extending through, and distally from, the skin engaging surface to the reservoir. A needle cannula having a sharpened proximal end and a distal end may be provided in the channel. The needle cannula is secured in the channel with the distal end being in communication with the reservoir and the proximal end of the needle cannula extending from the skin engaging surface a distance in the range of about 0.5 mm to 3.0 mm such that the skin engaging surface limits penetration of the proximal end of the needle cannula to the dermis layer of the skin of a patient.
Description

This application claims priority to U.S. Provisional Appl. No. 60/498,508, filed August 28, 2003.

FIELD OF THE INVENTION

The present invention relates to an intradermal injection device.

BACKGROUND

Drug substances may be delivered into a patient's body via injection into the muscle, subcutaneous tissue, or into the epidermis and dermis (also referred to as an intradermal injection). The efficacy of a particular drug substance may change when the drug is delivered intradermally. In some cases, intradermal delivery may be more beneficial to the patient. There is considerable variation in the skin thickness both between individuals and within the same individual at different sites of the body. Generally, the outer skin layer epidermis has a thickness ranging from 50 to 200 microns, and the dermis, the inner and thicker layer of the skin, has a thickness ranging from 1.5 to 3.5 mm. Therefore, a needle cannula that penetrates the skin deeper than about 3 mm has a potential of passing through the dermis layer of the skin, thus making the injection into the subcutaneous region, which may result in an insufficient immune response, especially where the substance to be delivered intradermally has not been indicated for subcutaneous injection. Also, the needle cannula may penetrate the skin at too shallow a depth to deliver the substance and result in what is commonly known in the art as a "wet injection" due to reflux of the substance from the injection site.

The standard procedure for making an intradermal injection, generally referred to as the Mantoux procedure, is difficult to perform, and successful administration of an intradermal injection using that procedure depends upon experience and technique of the person using the injection device. The Mantoux procedure requires that the user of the injection device stretch the skin, orient the needle bevel to face upwardly, and insert a 26 gauge short bevel needle cannula to deliver a volume of 0.5 ml or less of the drug substance into the skin of the patient. During this procedure, the needle cannula must be maintained at an angle varying from around 10° to 15° with respect to the patient's skin to form a blister or wheal in which the drug substance is deposited or otherwise contained. The above-described technique is difficult to perform and typically requires the attention of a trained nurse or medical doctor. Inserting the needle to a depth greater than about 3 mm typically results in a failed intradermal injection because the drug substance being expelled through the cannula will be injected into the subcutaneous tissue of the patient.

As disclosed in United States Patent Application Publication No. 2002/0068909 A1, which published on June 6, 2002, and United States Patent No. 6,494,865 B1, which issued on December 17, 2002, both to the assignee herein, an intradermal needle assembly has been developed for use with a prefillable container having a reservoir capable of storing a drug substance for injection into the skin of a patient. A needle cannula is supported by the prefillable container and has a forward tip extending away from the container. The intradermal needle assembly includes a limiter that is securable to the prefillable container and which surrounds the needle cannula and provides a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of the needle cannula. The flat skin engaging surface is adapted to be received against the skin of the patient during administration of the intradermal injection. The needle forward tip extends beyond the skin engaging surface a distance of approximately 0.5 to 3 mm. Therefore, the limiter limits penetration of the needle into the dermis layer of the skin of the patient so that the drug substance is injected into the dermis layer of the patient.

SUMMARY OF THE INVENTION

The present invention is directed to an intradermal injection device comprising a unitary body having an open distal end and a proximal end having a skin engaging surface defined thereon; a reservoir defined between the proximal and distal ends for accommodating a drug substance; and a channel defined at the proximal end of the unitary body and extending through, and distally from, the skin engaging surface to the reservoir. Further, the device comprises a needle cannula having a sharpened proximal end and a distal end. The needle cannula is secured in the channel with the distal end being in communication with the reservoir and the proximal end of the needle cannula extending from the skin engaging surface a distance in the range of about 0.5 mm to 3.0 mm such that the skin engaging surface limits penetration of the proximal end of the needle cannula to the dermis layer of the skin of a patient.

In a further aspect of the subject invention, a protrusion is provided on the proximal end of the body of the device which extends proximally from a first surface portion. Preferably, the protrusion is annular and circumscribes the channel. The protrusion aids in the injection process by providing a good interface between the device and the patient's skin, limiting leakage from the injection site during the injection process.

In yet a further aspect of the subject invention, a holder for a medicament comprising the unitary body is provided to which a needle cannula may be affixed.

Advantageously, with the subject invention, a needle cannula is "staked" or directly affixed to an injection body or holder for a medicament to form an intradermal injection device, without the use of a separate limiter. The subject invention is particularly well-suited to be used as a glass prefillable intradermal syringe, although other
applications are possible.

As used herein, distal shall refer to a part or direction located away or furthest from a patient, whole proximal shall refer to a part or direction towards or located nearest to a patient. Also, a drug substance is used herein in an illustrative, non-limiting manner to refer to any substance injectable into the body of a patient for any purpose. Reference to a patient may be to any being, human or animal.

These and other features of the subject invention shall be better understood through a study of the following detailed description and accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, which are not to scale, and in which like reference characters denote similar elements throughout the several views:

Figure 1 is a side partial cross-sectional view of an intradermal injection device constructed in accordance with an embodiment of the present invention;

Figure 2 is an enlarged partial view of Section 2 in Figure 1;

Figure 3 is a top view of the intradermal injection device depicted in Figure 2, as viewed from line 3-3;

Figure 4 is an elevational side view of a body of an intradermal injection device, constructed in accordance with an embodiment of the present invention;

Figure 5 is an enlarged partial view of Section 5 in Figure 4;

Figure 6 is a partial side view of a body of an intradermal injection device having a protrusion extending therefrom constructed in accordance with an embodiment of the present invention;

Figure 7 is a top view of the intradermal injection device depicted in Figure 6, as viewed from line 7-7;

Figure 8 is a cross-sectional view taken from line 8-8 of Figure 7 without the needle cannula or adhesive being shown; and,

Figures 9a-9b depict various cross-sections which may be used alternatively to the cross-section shown in Figure 8.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Figures 1-3 depict an intradermal injection device 100 constructed in accordance with an embodiment of the present invention. The injection device 100 is preferably a syringe comprised of a body 10 having a barrel 20, an open distal end 40 with a flange 22, a proximal end 30, and a reservoir 24 defined therebetween. A drug substance may be placed in the reservoir 24 before the injection device 100 is provided to the end user. The injection device 100 also includes a plunger 80 slidingly and sealingly provided within the reservoir 24, and a plunger rod 90 secured to the plunger 80 to facilitate movement of the plunger 80 within the reservoir 24 to effect expulsion of the drug substance therefrom.

The body 10 narrows near the proximal end 30 to form a neck 28 that supports a limiter 50 defined at the proximal end 30 of the body 10. The neck 28 is preferably tapered, particularly to converge in a distal to proximal direction. A first transition 32 may be provided to accommodate a gradual change in the outer diameter between the barrel 20 and the neck 28, and a second transition 34 may be provided to accommodate a gradual change in outer diameter between the neck 28 and limiter 50. The transitions 32, 34 may be chamfered, radiused, or otherwise softened to avoid forming sharp, e.g., right angle, transitions between the various elements.

The limiter 50 defines a skin engaging surface 52 at its proximal end that contacts the skin of a patient during use of the injection device 100. The limiter 50 and skin engaging surface 52 are unitarily formed with the body 10. The skin engaging surface 52 may be formed flat or with any known configuration, including, but not limited to, those surface configurations disclosed in co-pending Appl. No. [Attorney Reference No. 102-530 (P-5612)], the entire disclosure of which is incorporated herein by reference.

With reference to Figure 5, the limiter 50 preferably has a cylindrical shape and defines an outer diameter d which is less than or equal to 11 mm, more preferably less than or equal to 5.5 mm. Outer perimeter 54, formed at the intersection of the skin engaging surface 52 and side surface 56 of the limiter 50, is preferably chamfered, radiused or otherwise softened to avoid defining a sharp transition between the skin engaging surface 52 and the side surface 56.

A channel 26 extends through the skin engaging surface 52 and in a distal direction into communication with the reservoir 24. The channel 26 preferably has a central longitudinal axis which is generally perpendicular to a plane defined by the skin engaging surface 52. The channel 26 may have a constant diameter, or it may have a diameter varying in size from one approximately matched to the outer diameter of a needle cannula, and increasing to a size greater than the outer diameter of the needle cannula. In either case, a portion of the channel 26 preferably has a diameter sized and shaped to accommodate a needle cannula, as described in more detail below. For a varying diameter channel 26, it is preferred that the end of the channel 26 nearest the skin engaging surface 52 have a larger diameter than other portions of the channel 26 to receive an adhesive for securing the needle cannula in the channel 26. Also, for a varying diameter configuration, the cross-sectional profile of the channel 26 may be tapered, stepped, or any other configuration that permits variation in the diameter of the channel 26. In a preferred embodiment, such as is depicted in Figure 2, channel 26 has a first part 126 located near the skin engaging surface 52, and a second part 226, located near the reservoir 24. The first part 126...
has a diameter greater than that of the second part 226; the diameter of the second part 226 being preferably selected to be approximately the same as the outer diameter of the needle cannula provided as part of the inventive injection device 100. The outer diameter of the various gauges of needle cannula is well known in the art and the second part 226 may be sized accordingly. The channel 26 may optionally include a third part 336 provided adjacent the reservoir 24 to provide an at least partial transition between a bottom surface 124 of the reservoir 24 and the second part 226 of the channel 26. A similar transition may be provided between the first and second parts 126, 226 of the channel 26.

[0018] As shown in Figures 4 and 5, the body 10, which can act as a holder for medicament, can be provided alone. The body 10 in combination with a needle cannula 70 forms the injection device 100.

[0019] With reference to Figures 1 and 2, the needle cannula 70 is supported at the proximal end 30 of the body 10 in the channel 26 and includes a distal end 74 located in or near the reservoir 24 and a forward tip 72, preferably sharpened, that extends a predetermined distance d2 from the skin engaging surface 52. In a preferred embodiment, distance d2 ranges from approximately 0.5 mm to 3 mm. The distance d2 is preferably measured from a plane defined by coplanar portions of the skin engaging surface 52 (whether or not the skin engaging surface 52 is flat), more preferably, the distance d2 is measured from proximalmost portions of the skin engaging surface 52. The coplanar portions may be disposed continuously or discontinuously about the needle cannula 70. Preferably, the skin engaging surface 52 is formed to engage a patient’s skin such that a uniform ring of pressure is generated about the needle cannula 70 during injection. The ring of pressure assists in reduction in fluid leakage from the injection site during the injection process.

[0020] The distal end 74 is in fluid communication with the reservoir 24, and the needle cannula 70 provides a fluid path from the reservoir 24 through which the drug substance may be expelled from the injection device 100 and injected into the intradermal region in a patient’s skin. A central axis of the needle cannula 70, indicated as reference character 76 in Figure 2, is arranged at a predetermined angle with respect to a plane defined by the skin engaging surface 52, particularly the plane from which the distance d2 is measured as described above. In a preferred embodiment, that predetermined angle is approximately 90°. Other angular relationships are also contemplated by, and within the scope and spirit of, the present invention. Moreover, the angular relationship between the needle cannula central axis 76 and plane of the skin engaging surface 52 may be defined by variation on the placement of the needle cannula 70 in the channel 26, variation in the orientation of the skin engaging surface 52, or variation of both.

[0021] The needle cannula 70 is secured to the body 10 and within the channel 26 using a suitable adhesive 60 (see, e.g., Figure 3), particularly where the body 10 is formed of glass. In a preferred embodiment, the adhesive 60 is heat or ultraviolet curable. The amount of adhesive 60 used to secure the needle cannula 70 within the channel 26 is controlled so as to ensure that the flatness of the skin engaging surface 52 is not affected by the adhesive 60. Preferably, the amount of adhesive 60 provided does not completely fill the first part 126 of the channel 26, but instead, is recessed with regard to the skin engaging surface 52, e.g. by forming a generally concave surface. The first part 126 of the channel 26 conveniently provides a pocket for the adhesive 60 and it is not necessary to apply the adhesive 60 to other portions of the channel 26. As will be appreciated by those skilled in the art, the needle cannula 70 can be directly secured in the channel 26 using any known technique, such as being insert molded with the body 10 being formed of plastic.

[0022] The plunger rod 90 is connected at one end to the plunger 80 and having, at its other end, a thumb pad 92 that may be depressed by a user to cause movement of the plunger 80 within the reservoir 24 to expel the drug substance therefrom. When the plunger 80 is caused to move within the reservoir 24, the drug substance housed in the reservoir 24 is caused to be expelled therefrom. The plunger 80 may come into contact with the bottom surface 124 of the reservoir 24. Optionally, the plunger 80 may be forced onto the distal end 74 of the needle cannula 70 to sealingly engage the needle cannula 70. With this arrangement, the plunger 80 may thus seal the needle cannula 70 and prevent additional drug substance or other material from exiting the needle cannula 70 (either into the patient’s skin or elsewhere).

[0023] It is preferred that the body 10 of the inventive intradermal delivery device 100 be at least partially made from glass, preferably wholly, although other suitable materials that may be now known or hereafter developed may be used, including plastic. Although the inventive intradermal delivery device 100 may be used in various applications, it is particularly well-suited as a glass prefilled intradermal syringe.

[0024] In use, a drug substance is provided into the reservoir 24 and the plunger 80 is placed in the open distal end 40 of the barrel 20. As will be recognized by those skilled in the art, with the device being a prefilled device, the device 100 will be provided to a point-of-use with the drug substance and the plunger 80 being in the barrel 20 ready for use. With the device 100 not being prefilled, the plunger 80 is prepared and the drug substance is charged into the barrel by aspiration or other known methods at the point of use. Once ready, the inventive injection device 100 is preferably oriented in a generally perpendicular relationship with respect to the injection site. Thus, the central axis 76 of the needle cannula 70 is generally perpendicular to a plane defined by the patient’s skin at the injection site. Deviations from generally perpendicular typically will not adversely impact the use and efficiency of the inventive injection de-
vice 100. The forward tip 72 of the needle cannula 70 is
cased to pierce the patient's skin until the skin engaging
surface 52 contacts the patient's skin. The length of the
needle cannula 70 extending beyond the skin engaging
surface 52 and the skin engaging surface 52 itself serve
to limit the depth of penetration of the forward tip 72 of
the needle cannula to the intradermal space of the pa-
tient's skin. Upon full insertion, the health care provider
administering the injection depresses the thumb pad 92
to cause the plunger 80 to move in a distal to proximal
direction in the reservoir 24 thus causing expulsion of the
drug substance therefrom. Typically, the entire contents
of the reservoir 24 are administered in a single dose. That
is, each injection device 100 may be filled with a prede-
termined dose of a particular drug substance intended
for administration in a single dose. Once the drug sub-
stance has been effectively expelled and administration
of the injection is complete, the plunger 80 may be forced
to sealingly engage the distal end 74 of the needle can-
numla 70 and prevent further expulsion of drug substance
or other material through and from the needle cannula 70.

Although not shown in the figures, the inventive
injection device 100 may also include a safety component
that shields the forward tip 72 of the needle cannula 70
to reduce the possibility of accidental needle-stick injury
from occurring after use of the device 100. The safety
component may cover the forward tip 72 before use
and/or after use, and preferably locks in place after use
to prevent inadvertent exposure to the forward tip 72 after
use of the device 100. The safety component may com-
prise a holder for the body 10, a shield to cover the for-
ward tip 72 of the needle cannula 70, other components
that facilitate manual or assisted activation, or variations
and combinations thereof.

With reference to Figures 6-9b, and in a further
aspect of the subject invention, a protrusion 300 is pro-
vided to extend proximally from the proximal end of the
body 10. As indicated above, the skin engaging surface
52 may be formed with various configurations. Here, the
skin engaging surface 52 is defined on a free proximal
end 302 of the protrusion. A first surface portion 304 is
also defined on the proximal end 30 of the body 10. Prefer-
ably, the first surface portion 304 is flat, annular, and
circumscribes the protrusion 300. The protrusion 300 is
preferably annular and circumscribes the channel 26.
More preferably, the protrusion 300 bounds to channel
26, particularly the first part 126. With the skin engaging
surface 52 being defined on the protrusion 300, the sur-
rounding first surface portion 302 provides a wider base
for stability during an injection.

The protrusion 300 may be formed with various
cross-sectional shapes. In a most preferred embodiment,
and with reference to Figure 8, the protrusion is formed
with a rectangular cross-section, particularly a square
cross-section. The height h may be in the range of 0.2
mm to 0.5 mm and the width w of the free proximal end
302, and thus the skin engaging surface 52, may be in
the range of 0.2 mm to 0.5 mm. Of course, with a square

1. An intradermal injection device comprising:

a unitary body having an open distal end and a
proximal end having a skin engaging surface
defined thereon, a reservoir defined between said
distal and proximal ends for accommodating a
drug substance, and a channel defined at said
proximal end of said unitary body and extending
through, and distally from, said skin engaging
surface to said reservoir; and,

a needle cannula having a sharpened proximal
end and a distal end, said needle cannula being
secured in said channel with said distal end be-
ing in communication with said reservoir and
said proximal end of said needle cannula ex-
tending from said skin engaging surface a dis-
tance in the range of about 0.5 mm to 3.0 mm
such that said skin engaging surface limits pen-
netration of said proximal end of said needle can-
nula to the dermis layer of the skin of a patient.

2. A device as in 1, wherein said unitary body com-
prises glass.

3. A device as in 2, wherein said unitary body is formed wholly from glass.

4. A device as in 1, wherein said channel has a cross-sectional shape having a non-constant width.

5. A device as in 4, wherein said channel has a first portion located proximal said skin engaging surface and a second portion located proximal said reservoir, said first portion having a larger cross-sectional width than said second portion.

6. A device as in 5, wherein said needle cannula is secured in said channel with an adhesive, said adhesive being disposed in said first portion.

7. A device as in 1, wherein said body further comprises a barrel having an open distal end, said reservoir being defined in said barrel, a neck portion adjacent a proximal end of said barrel, and a limiter adjacent a proximal end of said neck portion, said skin engaging surface being defined on a proximal end of said limiter.

8. A device as in 7, wherein said barrel has a first outer diameter, said neck portion has a second outer diameter, and said limiter has a third outer diameter.

9. A device as in 8, wherein said outer diameter of said neck portion is tapered.

10. A device as in 7, wherein said limiter has an outer diameter that is no greater than 11 mm.

11. A device as in 7, wherein said limiter has an outer diameter that is no greater than 5.5 mm.

12. A device as in 1, wherein said skin engaging surface defines a plane disposed generally perpendicularly to a longitudinal axis of said needle cannula.

13. A device as in 1, wherein said skin engaging surface comprises portions that are substantially coplanar and that are disposed about said needle cannula.

14. A device as in 13, wherein said coplanar portions are disposed continuously about said needle cannula.

15. A device as in 13, wherein said coplanar portions are disposed discontinuously about said needle cannula.

16. A device as in 13, wherein said coplanar portions are defined on proximalmost portions of said skin engaging surface.

17. A device as in 1, further comprising a plunger slidably disposed in said reservoir.

18. A device as in 17, wherein said plunger sealingly engages said distal end of said needle cannula upon a predetermined extent of sliding movement in said reservoir.

19. A device as in 17, further comprising a plunger rod for selective attachment to said plunger, said plunger rod being configured to force sliding movement of said plunger within said reservoir.

20. A device as in 1, wherein said needle cannula is secured in said channel with an adhesive.

21. A device as in 20, wherein said adhesive is recessed in said channel below said skin engaging surface.

22. An intradermal injection device comprising: a unitary body having a open distal end and a proximal end having a first surface portion and a protrusion extending therefrom, a reservoir defined between said distal and proximal ends for accommodating a drug substance, and a channel defined at said proximal end of said unitary body and extending through, and distally from, said proximal end; and, a needle cannula having a sharpened proximal end and a distal end, said needle cannula being secured in said channel with said distal end being in communication with said reservoir and said proximal end of said needle cannula extending from said protrusion a distance in the range of about 0.5 mm to 3.0 mm such that said protrusion limits penetration of said proximal end of said needle cannula to the dermis layer of the skin of a patient.

23. A device as in 22, wherein said protrusion is generally annular and circumscribes said channel.

24. A device as in 23, wherein said protrusion bounds said channel.

25. A device as in 22, wherein said protrusion has a polygonal cross-section.

26. A device as in 25, wherein said protrusion has a generally rectangular cross-section.

27. A device as in 25, wherein said protrusion has a generally trapezoidal cross-section.
28. A device as in 25, wherein said protrusion has a generally square cross-section.

29. A device as in 25, wherein said protrusion has a height ranging from 0.2 to 1.0 mm, said protrusion terminating at a proximal free end, said proximal free end defining a width ranging from 0.2 to 0.6 mm.

30. A device as in 26, wherein said protrusion has a height and width, each ranging from 0.2 to 0.5 mm.

31. A device as in 27, wherein said protrusion has a height ranging from 0.5 to 1.0 mm, said protrusion terminating at a proximal free end, said proximal free end defining a width ranging from 0.35 to 0.6 mm.

32. A device as in 28, wherein said protrusion has a height and width, each ranging from 0.2 to 0.5 mm.

33. A device as in 22, wherein at least a portion of the cross-section of said protrusion is arcuate.

34. A device as in 22, wherein proximalmost portions of said protrusion are disposed continuously about said needle cannula.

35. A device as in 22, wherein proximalmost portions of said protrusion are disposed discontinuously about said needle cannula.

36. A device as in 22, wherein first surface portion circumscribes said protrusion.

37. A device as in 22, wherein first surface portion is generally annular.

38. A device as in 22, wherein first surface portion is generally planar.

39. A device as in 22, wherein said unitary body comprises glass.

40. A device as in 39, wherein said unitary body is formed wholly from glass.

41. A device as in 22, wherein said channel has a cross-sectional shape having a non-constant width.

42. A device as in 41, wherein said channel has a first portion located proximal said skin engaging surface and a second portion located proximal said reservoir, said first portion having a larger cross-sectional width than said second portion.

43. A device as in 42, wherein said needle cannula is secured in said channel with an adhesive, said adhesive being disposed in said first portion.

44. A device as in 22, wherein said body further comprises a barrel having an open distal end, said reservoir being defined in said barrel, a neck portion adjacent a proximal end of said barrel, and a limiter adjacent a proximal end of said neck portion, said first surface portion being defined on a proximal end of said limiter.

45. A device as in 44, wherein said barrel has a first outer diameter, said neck portion has a second outer diameter, and said limiter has a third outer diameter.

46. A device as in 45, wherein said outer diameter of said neck portion is tapered.

47. A device as in 44, wherein said limiter has an outer diameter that is no greater than 11 mm.

48. A device as in 44, wherein said limiter has an outer diameter that is no greater than 5.5 mm.

49. A device as in 22, wherein first surface portion defines a plane disposed generally perpendicularly to a longitudinal axis of said needle cannula.

50. A device as in 22, further comprising a plunger slidably disposed in said reservoir.

51. A device as in 50, wherein said plunger sealingly engages said distal end of said needle cannula upon a predetermined extent of sliding movement in said reservoir.

52. A device as in 50, further comprising a plunger rod for selective attachment to said plunger, said plunger rod being configured to force sliding movement of said plunger within said reservoir.

53. A device as in 22, wherein said needle cannula is secured in said channel with an adhesive.

54. A device as in 53, wherein said adhesive is recessed in said channel below said skin engaging surface.

55. A holder for a medicament comprising a unitary body comprising a generally tubular barrel having an open distal end and a proximal end, a reservoir for accommodating a medicament for intradermal delivery being defined between said distal and proximal ends of said generally tubular barrel, a neck portion adjacent said proximal end of said generally tubular barrel, a limiter adjacent a proximal end of said neck portion having a skin engaging surface defined therein, and a channel defined at said proximal end of said unitary body and extending through, and distally from, said skin engaging surface to said reservoir, said skin engaging surface limiting delivery of the...
medicament to the dermis layer of a patient’s skin.

56. A holder as in 55, wherein said channel has a cross-sectional shape having a non-constant width.

57. A holder as in 56, wherein said channel has a first portion located proximal said skin engaging surface and a second portion located proximal said reservoir, said first portion having a larger cross-sectional width than said second portion.

58. A holder as in 55, wherein said barrel has a first outer diameter, said neck portion has a second outer diameter, and said limiter has a third outer diameter.

59. A holder as in 58, wherein said outer diameter of said neck portion is tapered.

60. A holder as in 55, wherein said limiter has an outer diameter that is no greater than 11 mm.

61. A holder as in 55, wherein said limiter has an outer diameter that is no greater than 5.5 mm.

62. A holder as in 55, wherein said skin engaging surface defines a plane disposed generally perpendicularly to a longitudinal axis of said channel.

63. A holder as in 55, wherein said skin engaging surface comprises portions that are substantially coplanar and that are disposed about said channel.

64. A holder as in 63, wherein said coplanar portions are disposed continuously about said channel.

65. A holder as in 63, wherein said coplanar portions are disposed discontinuously about said channel.

66. A holder as in 55, wherein said skin engaging surface is defined on proximalmost portions of said limiter.

67. A holder as in 55, wherein said skin engaging surface has a protrusion extending therefrom.

68. A holder as in 67, wherein said protrusion is generally annular and circumscribes said channel.

69. A holder as in 68, wherein said protrusion bounds said channel.

70. A holder as in 67, wherein said protrusion has a polygonal cross-section.

71. A holder as in 70, wherein said protrusion has a generally rectangular cross-section.

72. A holder as in 70, wherein said protrusion has a generally trapezoidal cross-section.

73. A holder as in 70, wherein said protrusion has a generally square cross-section.

74. A holder as in 70, wherein said protrusion has a height ranging from 0.2 to 1.0 mm, said protrusion terminating at a proximal free end, said proximal free end defining a width ranging from 0.2 to 0.6 mm.

75. A holder as in 71, wherein said protrusion has a height and width, each ranging from 0.2 to 0.5 mm.

76. A holder as in 72, wherein said protrusion has a height ranging from 0.5 to 1.0 mm, said protrusion terminating at a proximal free end, said proximal free end defining a width ranging from 0.35 to 0.6 mm.

77. A holder as in 73, wherein said protrusion has a height and width, each ranging from 0.2 to 0.5 mm.

78. A holder as in 67, wherein at least a portion of the cross-section of said protrusion is arcuate.

79. A holder as in 67, wherein proximalmost portions of said protrusion are disposed continuously about said needle cannula.

80. A holder as in 67, wherein proximalmost portions of said protrusion are disposed discontinuously about said needle cannula.

81. A holder as in 67, wherein said first surface portion circumscribes said protrusion.

82. A holder as in 67, wherein said first surface portion is generally annular.

83. A holder as in 67, wherein said first surface portion is generally planar.

84. A holder as in 67, wherein said unitary body comprises glass.

85. A holder as in 84, wherein said unitary body is formed wholly from glass.

86. A holder as in 55, wherein said skin engaging surface defines a plane disposed generally perpendicularly to a longitudinal axis of said channel.

Claims

1. An intradermal injection device (100) comprising:

   a unitary body (10) comprising:
a barrel (20) having an open distal end (40) and a proximal end (30); a neck portion (28) adjacent the proximal end (30) of said barrel (20), and a limiter (50) adjacent a proximal end of said neck portion (28), said limiter (50) comprising a skin engaging surface (52) defined on a proximal end thereof; a reservoir (24) defined between said distal and proximal ends (40, 30) of said barrel (20) for accommodating a drug substance; and a channel (26) defined at said proximal end (30) of said barrel (20) and extending through, and distally from, said skin engaging surface (52) to said reservoir (24); and a needle cannula (70) having a sharpened proximal end and a distal end, said needle cannula (70) being secured in said channel (26) with said distal end being in communication with said reservoir (24) and said proximal end of said needle cannula (70) being proximal to said skin engaging surface (52) limiting penetration of said proximal end of said needle cannula (70) to the dermis layer of the skin of a patient.

2. A device as in claim 1, wherein said skin engaging surface (52) defined on a proximal end of said limiter (52) comprises a protrusion (300) extending therefrom.

3. A device as in claim 2, wherein said protrusion (300) is generally annular and circumscribes said channel (26).

4. A device as in claim 3, wherein protrusion (300) bounds said channel (26).

5. A device as in claim 2, wherein said protrusion (300) has a polygonal cross-section, preferably a rectangular cross-section, a square cross-section, or a trapezoidal cross-section.

6. A device as in claim 2, wherein said protrusion (300) has a height ranging from 0.2 to 1.0 mm, said protrusion (300) terminating at a proximal free end (302), said proximal free end (302) defining a width ranging from 0.2 to 0.5 mm.

7. A device as in claim 2, wherein proximal-most portions of said protrusion (300) are disposed discontinuously about said needle cannula (70).

8. A device as in claim 2, wherein proximal-most por-
FIG. 1
## DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 03/068290 A2 (ANTARES PHARMA INC [US]; SADOWSKI PETER L [US]; LESCH PAUL R JR [US]); 21 August 2003 (2003-08-21) * page 2, line 1 - page 9, line 26; figures 1-7 *</td>
<td>2-8</td>
<td>TECHNICAL FIELDS SEARCHED (IPC)</td>
</tr>
<tr>
<td>A</td>
<td>US 3 390 678 A (BRADLEY RONALD W ET AL) 2 July 1968 (1968-07-02) * column 2, line 62 - column 5, line 42; figures 1-4 *</td>
<td>1-15</td>
<td>A61M</td>
</tr>
<tr>
<td>A</td>
<td>EP 0 709 105 A1 (SCHOTT GLASWERKE [DE]) 1 May 1996 (1996-05-01) * column 5, line 45 - column 9, line 44; figures 1-5 *</td>
<td>1-15</td>
<td>A61M</td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims

**Place of search**
The Hague

**Date of completion of the search**
19 June 2018

**Examiner**
Dieterle, Sibille

**CATEGORY OF CITED DOCUMENTS**
- **X**: particularly relevant if taken alone
- **Y**: particularly relevant if combined with another document of the same category
- **A**: technological background
- **P**: intermediate document

**T**: theory or principle underlying the invention
**E**: earlier patent document, but published on, or after the filing date
**D**: document cited in the application
**L**: document cited for other reasons
**&**: member of the same patent family, corresponding document
This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on the European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 2003050602 A1</td>
<td>13-03-2003</td>
<td>BR 0212496 A</td>
<td>24-08-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2460063 A1</td>
<td>20-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1571685 A</td>
<td>26-01-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1432466 T3</td>
<td>03-12-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 1432466 A2</td>
<td>03-06-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2393282 T3</td>
<td>20-12-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 4383168 B2</td>
<td>16-12-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2005527249 A</td>
<td>15-09-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX 2903050602 A1</td>
<td>13-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2909157041 A1</td>
<td>18-06-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2015051582 A1</td>
<td>19-02-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 03002330 A2</td>
<td>20-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 200400969 B</td>
<td>27-07-2005</td>
</tr>
<tr>
<td>WO 03068290 A2</td>
<td>21-08-2003</td>
<td>AT 409057 T</td>
<td>15-10-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2003209095 A1</td>
<td>04-09-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0307589 A</td>
<td>01-02-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2475573 A1</td>
<td>21-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1476210 A2</td>
<td>17-11-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2314182 T3</td>
<td>16-03-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5060155 B2</td>
<td>31-10-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2005516737 A</td>
<td>09-06-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 200722661 A</td>
<td>06-09-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2012024600 A</td>
<td>09-02-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2014166691 A</td>
<td>18-09-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20040100930 A</td>
<td>09-12-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009032324 A1</td>
<td>10-02-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012179010 A1</td>
<td>12-07-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 201321562 A1</td>
<td>05-09-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2014303558 A1</td>
<td>09-10-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2016213859 A1</td>
<td>28-07-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2017340838 A1</td>
<td>30-11-2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 03068290 A2</td>
<td>21-08-2003</td>
</tr>
<tr>
<td>US 3390678 A</td>
<td>02-07-1968</td>
<td>US 3390678 A</td>
<td>02-07-1968</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 3430627 A</td>
<td>04-03-1969</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0709105 A1</td>
<td>01-05-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3249035 B2</td>
<td>21-01-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP H082006201 A</td>
<td>13-08-1996</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82.
This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-06-2018

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 6331174 B1</td>
<td>18-12-2001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 49850803 P [0001]
- US 20020068909 A1 [0005]
- US 6494865 B1 [0005]